FIELD: medicine.
SUBSTANCE: invention relates to a method of treating cancer using a combination therapy comprising a dual insulin receptor substrate (IRS) modulator and a signal transducer and transcription activator 3 (Stat3) in combination with an antibody to programmed cell death protein 1 (PD-1), with an antibody to programmed cell death protein ligand 1 (PD-L1), or a combination thereof.
EFFECT: combination can be used to resensitize a tumor that may or has already developed resistance to anti-PD-1 and/or PD-L1 antibody by enhancing the tumor response to anti-PD-1 antibody and/or anti-PD-L1 antibody, converting non-responsive tumors in tumors in which there is a response, and/or blocking tumor progression.
9 cl, 1 dwg, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMBINATION THERAPY WITH A CHEMOKINE RECEPTOR 2 (CCR2) ANTAGONIST AND A PD-1/PD-L1 INHIBITOR | 2018 |
|
RU2796863C2 |
| REDUCTION OF TUMOR MASS BY INJECTING CCR1 ANTAGONISTS IN COMBINATION WITH PD-1 INHIBITORS OR PD-L1 INHIBITORS | 2017 |
|
RU2745195C2 |
| ANTI-PD-L1 ANTIBODY AND ITS USE | 2020 |
|
RU2783685C2 |
| NOVEL APPROACH TO CANCER TREATMENT USING IMMUNOMODULATION | 2016 |
|
RU2817047C2 |
| COMBINED METHODS FOR TREATING WITH PD-L1 ANTAGONISTS | 2016 |
|
RU2766890C2 |
| ANTI-LIGAND 1 ANTIBODY OF PROGRAMMED CELL DEATH (PD-L1), ITS ANTIGEN-BINDING FRAGMENT AND THEIR MEDICAL APPLICATION | 2016 |
|
RU2727914C2 |
| NEW MONOCLONAL ANTIBODIES TO PROGRAMMED CELL DEATH 1 (PD-1) PROTEIN | 2016 |
|
RU2757316C2 |
| ANTIBODIES TO PD-1 | 2015 |
|
RU2715628C2 |
| ANTI-PD-L1 ANTIBODIES AND METHODS FOR THEIR DIAGNOSTIC USE | 2015 |
|
RU2715038C2 |
| COMBINATION OF TASQUINIMOD OR ITS PHARMACEUTICALLY ACCEPTABLE SALT AND PD-1 AND/OR PD-L1 INHIBITOR FOR USE AS A MEDICINAL AGENT | 2016 |
|
RU2742373C2 |
